Blood Testing for Vascular Ehlers-Danlos Syndrome
There is no blood test for vascular Ehlers-Danlos syndrome (vEDS)—diagnosis requires genetic testing for COL3A1 pathogenic variants, which is mandatory for confirmation and cannot be replaced by clinical criteria alone. 1, 2
Diagnostic Testing Algorithm
Required Molecular Testing
- Genetic testing for COL3A1 pathogenic variants is the only confirmatory test for vEDS 1, 2
- Testing can be performed via:
- Direct genetic sequencing of COL3A1 gene
- Skin biopsy with fibroblast culture for collagen analysis (historical method, less commonly used) 3
- Identification of a causal COL3A1 variant is a requirement for diagnosis 1
Critical Diagnostic Pitfall
Clinical diagnostic criteria alone are insufficient and lead to misdiagnosis. Studies demonstrate that 44% of patients diagnosed clinically without genetic confirmation do not actually have vEDS 3. These misdiagnosed patients show:
- Higher rates of mitral valve prolapse (10.5% vs 1.2%)
- More joint hypermobility (68.4% vs 40.7%)
- Lower rates of characteristic features like easy bruising (23.7% vs 64%) and thin translucent skin (17.1% vs 48.8%) 3
When to Order Genetic Testing
Order COL3A1 genetic testing when patients present with:
Major arterial complications before age 40:
- Spontaneous arterial dissection or rupture
- Medium-sized artery aneurysms
- Arteriovenous fistulas
- Aortic dissection (occurs in up to 10% of vEDS patients) 1
Characteristic clinical features:
- Thin, translucent skin with visible veins
- Easy bruising (ecchymotic tendency)
- Characteristic facial features (thin nose, lobeless ears, prominent eyes)
- Acrogeric appearance (aged-looking hands)
- Small joint hypermobility (NOT generalized hypermobility) 3, 4
Organ complications:
Positive family history of early arterial events or confirmed vEDS 4
Interpretation Requirements
Not all COL3A1 variants are pathogenic—interpretation by a geneticist or specialist trained in variant assessment is essential 3. Null variants (producing no gene product) paradoxically show better outcomes than missense variants 1.
Why This Matters for Mortality and Morbidity
- Life expectancy in confirmed vEDS averages 51 years 1
- Recurrence rate of major complications is 1.6 events per 5-year period 1
- Accurate genetic diagnosis enables:
The Villefranche clinical criteria have 79% sensitivity but only 60% specificity in symptomatic patients, and perform even worse in patients under 25 years old 4. This unacceptably high false-positive rate makes genetic confirmation non-negotiable.